{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:53:59Z","timestamp":1790801639048,"version":"4.1.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"crossref","award":["HHSO100201900007C"],"award-info":[{"award-number":["HHSO100201900007C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cefepime\/taniborbactam is a cephalosporin\/bicyclic boronate \u03b2-lactamase inhibitor combination in clinical development for nosocomial pneumonia due to MDR Gram-negative bacteria. A murine pneumonia model was used to characterize cefepime\/taniborbactam in vivo pharmacodynamics against Enterobacterales and Pseudomonas aeruginosa strains.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Clinical cefepime-non-susceptible Enterobacterales and P. aeruginosa strains expressing serine carbapenemases and\/or other cefepime-hydrolysing \u03b2-lactamases with cefepime\/taniborbactam combination MICs of 0.12\u201316 mg\/L were used. Cefepime and taniborbactam human-simulated regimens equivalent to clinical doses (i.e. 2\/0.5 g q8h) were established in the pneumonia model. The in vivo activity of the cefepime human-simulated regimen given alone or concomitantly with escalating taniborbactam exposures against eight Enterobacterales and four P. aeruginosa strains was assessed. Taniborbactam pharmacokinetics were evaluated to determine systemic exposures of regimens used; taniborbactam fAUC0\u201324\/MIC values required for efficacy were estimated using the Hill equation. In addition, the in vivo activity of the cefepime\/taniborbactam combination human-simulated regimen was assessed against 18 strains.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among Enterobacterales, median taniborbactam fAUC0\u201324\/MIC values associated with stasis and 1 log kill were 0.96 and 4.03, respectively, while for P. aeruginosa, requirements were 1.35 and 3.02 for stasis and 1 log kill, respectively. The cefepime\/taniborbactam human-simulated regimen produced &amp;gt;2 log kill in 14\/18 strains and &amp;gt;1 log kill in 18\/18 strains.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Cefepime\/taniborbactam produced marked in vivo bactericidal activity against cefepime-non-susceptible Enterobacterales and P. aeruginosa isolates with cefepime\/taniborbactam MICs up to and including 16 mg\/L in the pneumonia model. Assessments of the probability of clinical attainment of the identified targets should be undertaken to support the selected cefepime\/taniborbactam dose for treatment of nosocomial pneumonia.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkac446","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T13:27:39Z","timestamp":1673702859000},"page":"692-702","source":"Crossref","is-referenced-by-count":29,"title":["<i>In vivo<\/i>pharmacokinetic\/pharmacodynamic evaluation of cefepime\/taniborbactam combination against cefepime-non-susceptible Enterobacterales and<i>Pseudomonas aeruginosa<\/i>in a murine pneumonia model"],"prefix":"10.1093","volume":"78","author":[{"given":"Kamilia","family":"Abdelraouf","sequence":"first","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6036-3263","authenticated-orcid":false,"given":"David P","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, CT , USA"},{"name":"Division of Infectious Diseases, Hartford Hospital , Hartford, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,14]]},"reference":[{"key":"2023030208084465800_","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023030208084465800_","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/14656566.2018.1438408","article-title":"Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria","volume":"19","author":"Kidd","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"2023030208084465800_","doi-asserted-by":"crossref","first-page":"e01963-19","DOI":"10.1128\/AAC.01963-19","article-title":"VNRX-5133 (taniborbactam), a broad-spectrum inhibitor of serine- and metallo-\u03b2-lactamases, restores activity of cefepime in Enterobacterales and Pseudomonas aeruginosa","volume":"64","author":"Hamrick","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030208084465800_","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/jac\/dkz532","article-title":"Metallo-\u03b2-lactamase resistance in Enterobacteriaceae is an artefact of currently utilized antimicrobial susceptibility testing methods","volume":"75","author":"Asempa","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023030208084465800_","author":"Hackel"},{"key":"2023030208084465800_","author":"CLSI","year":"2022"},{"key":"2023030208084465800_","author":"CLSI","year":"2018"},{"key":"2023030208084465800_","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00253-22","article-title":"Safety and pharmacokinetics of taniborbactam (VNRX-5133) with cefepime in subjects with various degrees of renal impairment","volume":"66","author":"Dowell","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030208084465800_","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1128\/AAC.36.11.2439","article-title":"Comparison of the antibacterial effects of cefepime and ceftazidime against Escherichia coli in vitro and in vivo","volume":"36","author":"Mattie","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030208084465800_","author":"ClinicalTrials.gov"},{"key":"2023030208084465800_","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1093\/jac\/dkaa373","article-title":"In vivo pharmacodynamics of new-generation \u03b2-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-\u03b2-lactamase-producing Gram-negative bacteria","volume":"75","author":"Abdelraouf","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023030208084465800_","article-title":"Comparative in vivo efficacies of tedizolid in neutropenic versus immunocompetent murine Streptococcus pneumoniae lung infection models","volume":"61","author":"Abdelraouf","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030208084465800_","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1152\/jappl.1986.60.2.532","article-title":"Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution","volume":"60","author":"Rennard","year":"1986","journal-title":"J Appl Physiol (1985)"},{"key":"2023030208084465800_","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jac\/dkab405","article-title":"Clinical exposure\u2013response relationship of cefepime\/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model","volume":"77","author":"Lasko","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2023030208084465800_","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.coph.2017.09.004","article-title":"In vivo infection models in the pre-clinical pharmacokinetic\/pharmacodynamic evaluation of antimicrobial agents","volume":"36","author":"Andes","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"2023030208084465800_","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02307-18","article-title":"Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans","volume":"63","author":"Bulitta","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030208084465800_","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies","volume":"37","author":"Pang","year":"2019","journal-title":"Biotechnol Adv"},{"key":"2023030208084465800_","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1128\/AAC.00372-11","article-title":"Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates","volume":"55","author":"Keel","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030208084465800_","author":"ClinicalTrials.gov"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/3\/692\/49376253\/dkac446.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/3\/692\/49376253\/dkac446.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T15:17:02Z","timestamp":1679152622000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/3\/692\/6987586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,14]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,1,14]]},"published-print":{"date-parts":[[2023,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac446","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,2]]},"published":{"date-parts":[[2023,1,14]]}}}